Giacomo Gambineri
There has been a lot of talk of bubbles over the past year. I don’t mean the pandemic kind but rather being stuck in an echo chamber, hearing from people with similar values and perspectives on life. It’s a concept with which we’ve become pretty familiar, especially in the US, which just went through one of the most divisive presidential elections in its history. The media that we trust, the social media feeds we follow and our own social circles have all become more insulated.
It’s a separation that, on some measures, has become starker than…
Between Hollywood and the Moon, the options are endless for one of the world s richest men
3 February 2021 • 8:02am
Jeff Bezos is devoting more time to his rocket company Blue Origin
Credit: MICHAEL REYNOLDS/EPA-EFE/Shutterstock
Former Amazon executives will tell you that Jeff Bezos likes control. The billionaire’s love of “six pagers” – a lengthy memo read out loud at the beginning of each Amazon meeting – along with his interest in every single nut and bolt keeping the $1.7 trillion company running, made his bombshell decision to quit as chief executive all the more surprising.
“I won’t go as far as to say he was a micromanager, but he was a micromanager” says Jon Reily, a former Amazon hardware executive who worked with Bezos for five years, and recalls the Amazon founder getting deeply involved in how menus worked on Amazon’s touchscreen tablets. “That is just his personality.”
Jericho Project Welcomes CFO and COO of charity: water Aditi Deeg to Its Board
Share Article
Aditi Deeg, Jericho Project Board Member
We are honored to have Aditi Deeg bring her extensive leadership experience to our Board. We welcome her tremendous talent in achieving financial efficiencies while motivating teams with optimism as we move forward as an organization. Jericho Project Board President Mimi Boublik NEW YORK (PRWEB) January 29, 2021 Jericho Project, a nationally-acclaimed nonprofit ending homelessness at its roots, has welcomed Aditi Deeg, Chief Financial and Operating Officer at charity: water and strategic nonprofit leader, to its Board of Directors.
Published: Jan 29, 2021
BOSTON and LONDON, Jan. 29, 2021 (GLOBE NEWSWIRE) Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the appointment of Braden Parker to the role of Chief Commercial Officer (CCO). In this capacity, Mr. Parker will oversee all aspects of commercial strategy, planning and operations for the company. Mr. Parker is a seasoned commercial leader with more than 20 years of experience in the healthcare and biotech industry, including deep rare disease and gene therapy experience. Mr. Parker’s previous positions include commercial leadership roles at Celgene, NPS Pharma (Shire) and PTC Therapeutics, where he led the company’s first U.S. product launch in Duchenne muscular dystrophy and oversaw the strategic planning for their gene therapy business. Most recently, Mr. Parker served as Orchard’s senior vice president and general manager for North America.